Physician profile
John C Hervert
NPI 1235428921
$12,218.49
in general payments reported to CMS, 2019-2025
57 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $1,328 · 2021: $1,580 · 2022: $1,788 · 2023: $2,476 · 2024: $1,982 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,182.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,143.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,885.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,462.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,213.50 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $977.20 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $635.77 | 2019-2025 | Jardiance |
| Pfizer INC. | $444.05 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $363.92 | 2019-2025 | |
| Glaxosmithkline, LLC. | $307.95 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $167.27 | 2019-2025 | Spravato |
| Astellas Pharma US INC | $164.19 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $161.38 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.17 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $149.65 | 2019-2021 | |
| Allergan, INC. | $143.15 | 2020 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hervert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.